Selectively Targeting Mutant BRAF in Thyroid Cancer
Open Access
- 1 January 2010
- journal article
- other
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 95 (1) , 60-61
Abstract
Disclosure Summary: The author has nothing to declare.Keywords
This publication has 12 references indexed in Scilit:
- Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors inBRAFMutant Thyroid Carcinoma CellsThe Journal of Clinical Endocrinology & Metabolism, 2010
- Phase II Trial of Sorafenib in Advanced Thyroid CancerJournal of Clinical Oncology, 2008
- BRAFV600E Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up StudyThe Journal of Clinical Endocrinology & Metabolism, 2008
- BRAFV600E Mutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell LinesThe Journal of Clinical Endocrinology & Metabolism, 2008
- Selective Growth Inhibition in BRAF Mutant Thyroid Cancer by the Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244The Journal of Clinical Endocrinology & Metabolism, 2007
- BRAF Mutations in Papillary Thyroid Carcinomas Inhibit Genes Involved in Iodine MetabolismThe Journal of Clinical Endocrinology & Metabolism, 2007
- BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid CancerThe Journal of Clinical Endocrinology & Metabolism, 2005
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- BRAF Mutation in Papillary Thyroid CarcinomaJNCI: Journal of the National Cancer Institute, 2003
- Raf induces NF-κB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformationProceedings of the National Academy of Sciences, 2000